Phase 2a RCT in 85 patients with rheumatoid arthritis and inadequate response to methotrexate: branebrutinib 9 mg once daily did not improve ACR50 at week 12 vs placebo (19% vs 33%, p=0.16); adverse events were similar (47% vs 38%).
RCTn = 85
Østergaard et al. Efficacy and safety of branebrutinib (BMS-986195), an irreversible Bruton's tyrosine kinase inhibitor, for the treatment of rheumatoid arthritis: a phase 2a, randomised, double-blind, placebo-controlled study